CBD is cannabis’ best friend. Short for cannabidiol, CBD is the main component of marijuana that gives patients health benefits. CBD is non-psychoactive meaning it won’t get you high. With research being done on CBD’s myriad of health benefits including cancer-fighting, pain reducing, reducing seizures and a list of others, CBD is set to become the next great investment market.
One of the main stocks in the CBD market is a company called GW Pharmaceuticals (NASDAQ: GWPH), a U.K. drug developer that currently markets a THC based drug in Europe for the treatment of multiple sclerosis. Data conducted by scientists at GW Pharmaceuticals showed that purified CBD can reduce seizures by about 40% in patients across the board. GW Pharmaceuticals because of this currently has a product that is in fact purified CBD called Epidiolex.
While 28 states have passed laws allowing medical marijuana, 16 states have passed laws allowing CBD oil to be prescribed by doctors. If a medicine like Epidiolex is approved by the FDA, it will be available across the country, regardless of state laws.
According to the Matt Karnes, founder of GreenWave Advisors, a marijuana industry research firm, CBD sales within the U.S. alone are expected to top $3 billion in sales by 2021. With the market on epilepsy treatment already in the billions range, the chance at a more effective medicine being approved leaves all that profit to be gained as well.
Since the success and use of Epidiolex has been based on patients who have tried everything to treat their epilepsy in the past, it would make sense for the drug to become the first line of action when patients have uncontrollable seizures.
Unfortunately at this time, there is no guarantee of FDA approval however it does seem likely as adequate research is highly available. CBD has the ability to treat diseases far beyond epilepsy so as research progresses, so will treatments.